European Journal of Molecular & Clinical Medicine

Background: Postpartum haemorrhage is still the primary cause of maternal
death, particularly in underdeveloped nations. We aimed to see how tranexamic
acid and oxytocin compare in terms of preventing postpartum haemorrhage and
lowering blood loss, hospital stay, morbidity, and death during vaginal
birth.Patients and methods: A prospective, randomised clinical trial study was
conducted on 92 pregnant women who were being prepared for vaginal delivery
and were divided into two groups: Group (A) (TXA group) (46 patients) received 1
gm of tranexamic acid and Group (B) (Non-TXA group) (46 patients) received 10
IU of oxytocin. Hemoglobin and hematocrit readings were tested before and 24
hours after vaginal delivery, and additional basic laboratory tests were
performed.Results: In our study, there was no significant difference in HB at the
pre-test, but the Non-TXA group was considerably lower at the post-test, and the
Non-TXA group had a significant reduction. At the pre-test, there was no
significant difference in HCT, but the Non-TXA group was considerably lower at
the post-test, and the Non-TXA group had a significant reduction. In the TXA
group, the difference in HCT was much smaller. The TXA group had considerably
less blood loss.Conclusion: The use of tranexamic acid during delivery may assist to
minimise blood loss. It is a low-cost and widely available medication. The use of
TXA reduces the requirement for uterotonics, lowering morbidity and mortality.